Engineered cardiac patches from hiPSC-derived cardiomyocytes Authors: Jonas Jawad, Mohammad Z. Khan, Tamer Jabsheh, Daryoush Javidi Published: 2026 ABSTRACT BackgroundHeart failure remains a leading global cause of morbidity and mortality, with limited capacity for myocardial regeneration following infarction. Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) have become a promising therapeutic resource due to their scalability, differentiation potential, and immunologic adaptability. Engineered cardiac patches, three-dimensional constructs of hiPSC-CMs combined with supporting cells and scaffolds, offer a strategy to deliver organized myocardium directly to injured hearts, overcoming the limitations of cell injection therapies.Scope of ReviewThis review synthesizes evidence from 2010 to early 2025, spanning rodent, porcine, and non-human primate models, as well as the first clinical trials of hiPSC-CM patches. We highlight recent advances in maturation protocols, vascularization strategies, and scaffold engineering, while discussing two distinct translational paradigms: short-term paracrine support versus long-term remuscularization under sustained immunosuppression.ResultsPreclinical studies show that engineered patches improve graft survival, with engraftment rates ranging from 5 to 15%, alongside enhanced vascularization, electrical coupling, and left ventricular function. In large animal models, patches scaled to clinically relevant sizes achieved durable integration and improved hemodynamics. Of note, arrhythmogenic risk was lower than in intramyocardial injection models. Early human trials in Japan and Germany confirm feasibility and safety, with preliminary evidence of efficacy, including preliminary evidence of improved left ventricular ejection fraction and upgrades in NYHA functional class. Immunogenicity, graft maturation, and manufacturing scalability remain key hurdles, though innovations such as gene-edited hypoimmunogenic lines, multipronged maturation strategies, and bioreactor-based production offer potential solutions.ConclusionsEngineered hiPSC-CM cardiac patches represent a rapidly advancing frontier in regenerative cardiology. While early data indicate technical feasibility and measurable functional benefits, broader adoption will depend on resolving challenges of immune compatibility, arrhythmia prevention, and large-scale manufacturing. With coordinated progress in science, engineering, and regulation, cardiac patches may evolve into a transformative therapy for heart failure. Introduction Heart failure is a major global health issue, affecting over 64 million people worldwide and contributing to substantial morbidity and mortality. Its prevalence is expected to rise with aging populations and improved survival rates after myocardial infarction. In adult humans, the myocardium has minimal regenerative capacity; consequently, injury from events like myocardial infarction leads to the formation of non-contractile scar tissue through fibrosis, rather than the regeneration of functional heart muscle. This adverse remodeling progressively impairs cardiac function, leading to heart failure. Over the last two decades, a range of cell-based regenerative therapies have been explored to remuscularize injured myocardium or mitigate adverse structural changes [1]. While early efforts utilized cell types like mesenchymal stem cells (MSCs) and cardiac progenitor cells, which primarily act through paracrine mechanisms, human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) represent as a particularly promising resource for true muscle regeneration [2]. Their advantages include a virtually unlimited supply, the ability for multilineage differentiation relevant to cardiac tissue, and the potential for creating autologous or HLA-matched grafts for immunocompatibility. Engineered cardiac patches, which include sheets or three-dimensional constructs containing hiPSC-CMs, often with supporting cells and scaffolds, represent an advanced strategy to deliver a high density of organized cardiomyocytes directly to the epicardial surface. This approach contrasts with intramyocardial injection of dissociated cells, offering superior mechanical reinforcement, improved cell retention, and a microenvironment conducive to cell survival and integration [2, 3]. This review provides a contemporary synthesis of the literature published between 2010 and early 2025, covering key pre-clinical results from rodent, porcine, and non-human primate models, as well as the initial human trials of hiPSC-CM patches. Unlike prior reviews, this article examines two emerging clinical paradigms: short-term engraftment for paracrine benefit versus long-term remuscularization enabled by sustained immunosuppression, assessing their respective translational potentials. We also detail key advances in cellular maturation, vascularization strategies, and arrhythmia prevention, while addressing the primary barriers to widespread clinical adoption, including immunological compatibility, scaled manufacturing, and regulatory hurdles. Fabrication of hiPSC-cardiomyocyte patches Cell source and differentiation Human induced pluripotent stem cells (hiPSCs) are generated by reprogramming adult somatic cells into a pluripotent state, enabling their differentiation into various cell types, including cardiomyocytes (hiPSC-CMs), through highly standardized and reproducible protocols [1, 2]. However, hiPSC-CMs cultured under standard conditions typically exhibit features of fetal or neonatal cardiomyocytes rather than mature adult ones. These immature characteristics include disorganized myofibril ultrastructure, underdeveloped calcium handling, and spontaneous beating (automaticity). This immaturity presents functional limitations for therapeutic use, as the electrophysiological profile of immature hiPSC-CMs can increase the risk of arrhythmias post-transplantation [4]. Several strategies have been developed to enhance the functional maturity of hiPSC-CMs prior to implantation, many of which also improve engraftment efficiency and proliferative potential [5]. These include extended culture duration, applying electrical pacing and mechanical stress, hormonal treatment (e.g., thyroid hormones), and metabolic conditioning, such as culturing in high-lactate, glucose-free media to promote oxidative metabolism [6, 7]. Three-dimensional (3D) cultivation systems have proven particularly effective, significantly enhancing sarcomeric organization, electrical stability, and contractile function compared to traditional 2D monolayers [8, 9]. Three-dimensional (3D) cultivation systems refer to approaches in which hiPSC-derived cardiomyocytes are organized within structured tissue constructs—such as scaffold-based patches or self-assembled engineered tissues—rather than cultured as planar monolayers. These systems enable physiologically relevant cell–cell and cell–matrix interactions and better recapitulate the mechanical, electrical, and biochemical environment of native myocardium, thereby promoting cardiomyocyte maturation and functional stability. Integrating non-myocyte cardiac cells such as endothelial cells, smooth muscle cells, and fibroblasts into engineered patches promotes tissue organization and physiological function. These co-culture strategies support vascularization, enhance force generation, and facilitate electrophysiological integration of the graft. For example, Gao et al. constructed fibrin-based patches incorporating hiPSC-derived cardiomyocytes, endothelial cells, and smooth muscle cells, which demonstrated adult-like expression profiles, increased contractile activity, and improved graft viability compared to cardiomyocyte-only patches [10]. Patch composition and scaffold strategies The scaffold forms the structural foundation of an engineered cardiac patch, providing mechanical integrity, guiding cell orientation, and facilitating nutrient transport [11–13]. An ideal scaffold must balance biocompatibility, mechanical strength, electrical conductivity, and biodegradability, while promoting vascularization and synchronized contraction [2, 11]. Scaffold-based strategies are generally categorized into three classes: natural, synthetic, and hybrid materials [2, 11]. Natural Scaffolds such as collagen, fibrin, decellularized extracellular matrix (dECM), and alginate, mimic the native cardiac ECM, presenting bioactive cues that support cell adhesion, survival, and differentiation [11, 12]. Collagen and fibrin, for instance, facilitate sarcomere organization and have been widely used in preclinical patch constructs. Decellularized myocardial ECM retains structural proteins and growth factors essential for cardiomyocyte maturation and host tissue integration [2, 11]. However, natural scaffolds often suffer from batch-to-batch variability, poor mechanical strength, and suboptimal degradation profiles. Synthetic Scaffolds made from bioresorbable polymers like polycaprolactone (PCL), polylactic acid (PLA), and polyglycolic acid (PGA), offer customizable mechanical properties, predictable degradation rates, and high reproducibility. These polymers can be engineered with micro- or nano-patterned topographies to direct cardiomyocyte alignment and enhance electrical conduction. Additionally, incorporating electrically conductive materials (e.g., polypyrrole, graphene, carbon nanotubes) can improve electrical coupling between the graft and host myocardium [4]. A primary limitation is their general lack of intrinsic bioactivity, often requiring surface functionalization with peptides or growth factors [2, 11]. Hybrid Scaffolds combine the bioactivity of natural materials with the tunable features of synthetic polymers to optimize both biological signaling and mechanical integrity [9, 11]. For example, fibrin-PCL composites have shown improved cardiomyocyte alignment and enhanced suture retention for surgical fixation. Another strategy involves pre-vascularizing the scaffold by pre-seeding it with endothelial cells or creating perfusable microchannels via 3D printing, which can accelerate host vessel infiltration and improve graft survival in the ischemic heart [4, 13]. Design and preconditioning parameters The success of a cardiac patch depends on optimizing key design parameters, including cell density, tissue thickness, and mechanical properties [14]. A high cell density enhances force production, electrical synchrony, and the overall remuscularization potential of the graft but risks central necrosis without adequate vascularization [10]. Patches thicker than 200–300 μm require an intrinsic vascular network to avoid hypoxic core death [10, 15]. The mechanical properties of the scaffold should mimic the stiffness of native myocardium (approximately 10–20 kPa) [11]. These mechanical properties are largely dictated by scaffold material composition and architecture, including polymer chemistry, fiber alignment, and crosslinking density. Overly stiff scaffolds can impede contraction, while overly compliant ones may lack the necessary mechanical integrity for surgical handling [11, 12]. Anisotropic scaffolds with aligned fibers promote cardiomyocyte orientation, optimizing conduction velocity and coordinated contraction [8, 9]. In vitro preconditioning can significantly enhance graft effectiveness. Dynamic culture in bioreactors with cyclic mechanical stretching improves sarcomere organization, while electrical pacing enhances gap junction expression and conduction velocity [8, 9, 16]. Metabolic conditioning, by shifting energy substrates from glucose to fatty acids, promotes an adult-like cardiomyocyte phenotype [6, 7]. Integrating these preconditioning protocols helps prevent early graft failure and reduces arrhythmia risk post-transplantation [4, 8]. GMP manufacturing and quality control Transitioning from laboratory-scale production to clinical-grade manufacturing requires adherence to Good Manufacturing Practice (GMP) standards [1]. This involves strict quality control to ensure product safety, consistency, and efficacy [1, 15]. Key release criteria for a clinical-grade cardiac patch include: Purity High purity of hiPSC-CMs (e.g., > 95% TNNT2+) is crucial to minimize the risk of teratoma formation from residual undifferentiated pluripotent cells.Identity Confirmation that the cells are bona fide cardiomyocytes with appropriate marker expression.Potency A functional assessment to ensure the patch can contract and meets predefined force generation or electrical activity thresholds.Sterility and Safety The final product must be free of microbial contaminants, endotoxins, and mycoplasma.Consistency GMP manufacturing aims to minimize batch-to-batch variability, a significant challenge with biological products. Purity High purity of hiPSC-CMs (e.g., > 95% TNNT2+) is crucial to minimize the risk of teratoma formation from residual undifferentiated pluripotent cells. Purity High purity of hiPSC-CMs (e.g., > 95% TNNT2+) is crucial to minimize the risk of teratoma formation from residual undifferentiated pluripotent cells. Identity Confirmation that the cells are bona fide cardiomyocytes with appropriate marker expression. Identity Confirmation that the cells are bona fide cardiomyocytes with appropriate marker expression. Potency A functional assessment to ensure the patch can contract and meets predefined force generation or electrical activity thresholds. Potency A functional assessment to ensure the patch can contract and meets predefined force generation or electrical activity thresholds. Sterility and Safety The final product must be free of microbial contaminants, endotoxins, and mycoplasma. Sterility and Safety The final product must be free of microbial contaminants, endotoxins, and mycoplasma. Consistency GMP manufacturing aims to minimize batch-to-batch variability, a significant challenge with biological products. Consistency GMP manufacturing aims to minimize batch-to-batch variability, a significant challenge with biological products. Automation and standardized, closed-system bioreactors are being developed to improve reproducibility, address standardization challenges, and scale up production [2, 9]. Preclinical evidence of effectiveness Rodent models Rodent models provided the initial in vivo proof-of-concept for hiPSC-derived cardiac patches [9, 17]. In an early study, Riegler et al. transplanted engineered heart muscle (EHM) into a rat model of myocardial infarction, observing high engraftment rates, vascularization, and improved left ventricular (LV) contractility [17]. Subsequent studies have focused on optimizing patch composition. Tiburcy et al. engineered a highly mature human myocardium that demonstrated enhanced force generation and electrophysiological stability in a guinea pig chronic injury model [8]. Funakoshi et al. found that using optimized hiPSC-CMs with greater proliferative capacity led to superior LV functional restoration in rat infarct models [5]. These studies established that engineered patches can survive, vascularize, electrically couple with host myocardium, and improve cardiac function in small animals [5, 8, 9, 17]. Porcine models Porcine models offer a more accurate representation of human cardiac anatomy and physiology [2]. Gao et al. transplanted large cardiac muscle patches, composed of hiPSC-CMs, endothelial cells, and smooth muscle cells, onto the infarcted hearts of pigs [10]. The patches exhibited high viability, successful vascularization, and well-ordered sarcomeres. Functionally, treated animals showed enhanced regional wall motion and a higher global ejection fraction compared to controls. More recently, Kawamura et al. validated the safety and efficacy of hiPSC-CM patches in a chronic heart failure pig model [15]. The treated group demonstrated significant improvements in LV systolic function and myocardial perfusion, with no evidence of graft-induced ventricular arrhythmia or tumorigenesis. In this review, cardiac spheroids are discussed as a comparative cell delivery strategy rather than a form of engineered cardiac patch. While spheroids represent three-dimensional aggregates of hiPSC-derived cardiomyocytes that can enhance cell–cell interactions and survival relative to dissociated cell injection, they lack the predefined architecture, mechanical support, and spatial organization characteristic of engineered cardiac patches. Inclusion of spheroid-based approaches therefore serves to contextualize alternative myocardial delivery paradigms and to highlight the potential advantages and limitations of structured patch-based therapies with respect to cell retention, arrhythmogenic risk, and scalability. Similar improvements in LV systolic function were observed in heart-failure animals treated with hiPSC-derived cardiac spheroids, an alternative three-dimensional cell delivery strategy, delivered intramyocardially [18]. These large-animal studies highlight the scalability of cardiac patches and the importance of vascular components for long-term graft viability [9, 10, 15, 18]. Non-human primate (NHP) models An early landmark study by Chong et al. demonstrated that transplantation of human embryonic stem cell–derived cardiomyocytes could regenerate injured myocardium in non‑human primates [19]. While graft survival and functional improvement were observed, this work highlighted challenges related to electrical integration. Shiba et al. later investigated intramyocardial injection of allogeneic hiPSC‑derived cardiomyocytes into infarcted macaque hearts [20]. Although the grafts formed new cardiac muscle and improved left ventricular function, transient ventricular arrhythmias were observed, a finding that reflects the electrophysiological risk associated with cardiomyocyte injection strategies. More recently, Jebran et al. (under the direction of Wolfram-H. Zimmermann) shifted to an engineered patch approach. Macaque iPSC-CMs were combined with stromal cells to create EHM patches, which were implanted onto the hearts of macaques with chronic heart failure [21]. The grafts survived long-term (up to 6 months), demonstrated dose-dependent thickening of the ventricular wall, and led to significant improvements in regional wall motion and global ejection fraction. Intensive monitoring revealed no ventricular arrhythmias or teratoma formation. Histopathology confirmed extensive vascularization of the grafts and the formation of connexin-43-positive gap junctions, indicating structural and electrical integration with the native myocardium. Recent primate work has further confirmed durable engraftment and long-term functional maturation of iPSC-derived cardiomyocytes, with sustained electrical coupling observed for more than a year [22]. These NHP studies provide a critical translational bridge, demonstrating that large, structured cardiac patches can durably engraft, restore contractile function, and maintain a favorable safety profile in a primate model [2, 19–22]. Arrhythmogenic risk remains a central safety concern in cardiomyocyte-based cardiac therapies and is strongly influenced by cell maturity, delivery method, and graft architecture. Patch-based delivery strategies may mitigate arrhythmias by promoting organized tissue structure, improved electrical coupling, and more uniform electromechanical integration compared to intramyocardial cell injection. Multiple approaches have been explored to further reduce arrhythmia risk, including electrical and mechanical preconditioning, metabolic maturation protocols, enrichment for ventricular cardiomyocyte subtypes, and optimization of graft geometry and thickness. In preclinical large-animal models, these strategies have been associated with improved conduction velocity, enhanced gap junction formation, and reduced incidence of ventricular tachyarrhythmias. These findings suggest that engineered cardiac patches can achieve functional remuscularization without compromising electrophysiological safety. The influence of sex as a biological variable remains an under-investigated area in most large-animal preclinical studies of cardiac regeneration. Key preclinical studies evaluating hiPSC-CM cardiac patches across rodent, porcine, and non-human primate models are summarized in Table 1. Table 1Select preclinical studies of hiPSC-CM cardiac patchesStudy (year)ModelPatch compositionImmunosuppressionKey findingsGao et al. 2018 [10]Pig MI4 × 2 cm fibrin patch with hiPSC-CMs + ECs + SMCs (cell number not specified)Yes↑ EF, ↓ infarct size, ↓ wall stress vs. control; graft vascularization; no significant arrhythmias noted; no tumors.Kawamura et al. 2024 [15]Pig MI3 scaffold-free hiPSC-CM cell-sheets (cell number not specified)Yes↑ LV function and perfusion by PET; no lethal arrhythmias; cells survived ≤ 8 weeks; no tumors. Paracrine effects prominent.Shiba et al. 2016 [19]Macaque MIhiPSC-CM suspension (~ 4 × 10⁸ cells injected intramyocardially)Yes (Systemic)Graft formation and improved EF; transient VT/VF episodes post-transplant; required immunosuppression; no tumors reported.Jebran et al. 2024 [21]Macaque HF20x EHM patches (40-200 M iPSC-CMs + stromal cells in collagen)Yes (Systemic)Graft retention > 6 months; ↑ regional function and EF; grafts fully vascularized; no arrhythmias or tumors observed; basis for human trial.hiPSC-CM induced pluripotent stem cell-derived cardiomyocyte, EC endothelial cell, SMC smooth muscle cell, EHM engineered heart muscle, EF ejection fraction, VT/VF ventricular tachycardia/fibrillation, HF heart failure, MI myocardial infarction. Table 1Select preclinical studies of hiPSC-CM cardiac patchesStudy (year)ModelPatch compositionImmunosuppressionKey findingsGao et al. 2018 [10]Pig MI4 × 2 cm fibrin patch with hiPSC-CMs + ECs + SMCs (cell number not specified)Yes↑ EF, ↓ infarct size, ↓ wall stress vs. control; graft vascularization; no significant arrhythmias noted; no tumors.Kawamura et al. 2024 [15]Pig MI3 scaffold-free hiPSC-CM cell-sheets (cell number not specified)Yes↑ LV function and perfusion by PET; no lethal arrhythmias; cells survived ≤ 8 weeks; no tumors. Paracrine effects prominent.Shiba et al. 2016 [19]Macaque MIhiPSC-CM suspension (~ 4 × 10⁸ cells injected intramyocardially)Yes (Systemic)Graft formation and improved EF; transient VT/VF episodes post-transplant; required immunosuppression; no tumors reported.Jebran et al. 2024 [21]Macaque HF20x EHM patches (40-200 M iPSC-CMs + stromal cells in collagen)Yes (Systemic)Graft retention > 6 months; ↑ regional function and EF; grafts fully vascularized; no arrhythmias or tumors observed; basis for human trial.hiPSC-CM induced pluripotent stem cell-derived cardiomyocyte, EC endothelial cell, SMC smooth muscle cell, EHM engineered heart muscle, EF ejection fraction, VT/VF ventricular tachycardia/fibrillation, HF heart failure, MI myocardial infarction. Select preclinical studies of hiPSC-CM cardiac patches hiPSC-CM induced pluripotent stem cell-derived cardiomyocyte, EC endothelial cell, SMC smooth muscle cell, EHM engineered heart muscle, EF ejection fraction, VT/VF ventricular tachycardia/fibrillation, HF heart failure, MI myocardial infarction. Clinical translation and initial trials The transition from preclinical success to human application marks a pivotal moment for cardiac regenerative medicine [15, 23, 24]. The design of first-in-human trials requires careful consideration of patient selection, endpoints, and ethical issues [1]. Inclusion criteria typically target patients with severe heart failure (e.g., LVEF < 35%, NYHA Class III-IV) who have exhausted standard medical options and are not candidates for transplantation [15, 24]. A major ethical challenge lies in defining appropriate control groups; in many early-phase trials, patients serve as their own controls, or outcomes are compared to historical data, as withholding a potentially beneficial therapy in a sham-operated group is difficult to justify [1]. Osaka University (Japan) - allogeneic hiPSC-CM patch trial In 2019, a team at Osaka University led by Yoshiki Sawa initiated the world’s first clinical trial of an allogeneic hiPSC-CM patch for patients with severe ischemic cardiomyopathy [24]. The trial utilized a clinical-grade hiPSC line from an HLA-homozygous donor to minimize immune mismatch. The graft consisted of three cell sheets, each containing approximately 3.3 × 10⁷ hiPSC-CMs, transplanted onto the LV epicardium. To mitigate rejection, patients received a three-month course of triple-agent immunosuppression (tacrolimus, prednisolone, mycophenolate) [24]. These preclinical findings provided the basis for the first-in-human trial [15]. By 2022, the team reported favorable early safety outcomes from the first three patients [25]. No serious adverse events, malignant arrhythmias, or tumorigenesis were observed at 6–12 months follow-up. All patients showed symptomatic improvement (NYHA class improved from III to II), and two demonstrated improved LV contractility and myocardial perfusion. Despite the transient immunosuppression, all patients developed anti-hiPSC-CM antibodies, indicating immune recognition of the graft. The durability of the functional benefits, even after immunosuppressant cessation, suggests a significant contribution from paracrine mechanisms, such as the secretion of pro-angiogenic and anti-fibrotic factors [15, 24]. Zimmermann/Repairon (Germany) - BioVAT-HF trial A distinct therapeutic strategy is being pursued in Germany by a consortium led by Wolfram-H. Zimmermann. The Biological Ventricular Assist Tissue (BioVAT) program developed an engineered human myocardium (EHM) patch therapy aimed at long-term remuscularization [21]. The BioVAT Phase I/II trial (NCT04396899), initiated in 2020, enrolls patients with end-stage heart failure [1, 21]. Unlike the Japanese trial, patients receive continuous, long-term immunosuppression, similar to heart transplant recipients. The EHM patches, containing up to 800 million hiPSC-CMs and stromal cells in a bovine collagen scaffold, are applied as an “off-the-shelf” allograft to the epicardium [21]. In late 2024, the team reported on the first patient treated. At 12-month follow-up, the high-dose therapy was well-tolerated, with no graft-related arrhythmias or tumors [21]. Examination of the patient’s heart following a subsequent transplant confirmed that the grafts had vascularized and electrically coupled with the host myocardium. Functionally, the treated ventricular segments showed sustained wall thickening, and the patient’s NYHA functional class and quality-of-life scores improved significantly. This trial provides the first direct human evidence that transplanted hiPSC-CM patches can survive long-term, integrate structurally, and contribute to active contractile force [2, 21]. Other clinical efforts Related strategies are also being explored. Heartseed Inc. in Japan is conducting the LAPIS Study, testing the transcoronary infusion of hiPSC-derived cardiac spheroids in heart failure patients [18]. This micro-tissue approach aims to improve cell retention compared to single-cell injections. Early data from the first patients indicate improved ejection fraction with no significant arrhythmias, which may be attributed to the use of highly purified ventricular myocytes [18, 24]. While the most advanced trials are in Japan and Germany, research and early-phase clinical efforts are also underway in other regions, including the United States and China, exploring different cell formulations and delivery systems [2]. Despite these encouraging early results, several clinical variables are likely to influence therapeutic efficacy. An important consideration for the clinical translation of hiPSC-derived cardiac patches is the underlying etiology of heart failure. Clinical and preclinical studies of cell-based cardiac therapies have suggested that therapeutic response may differ between ischemic and non-ischemic cardiomyopathy, reflecting differences in scar burden, myocardial perfusion, and patterns of ventricular remodeling. To date, most cardiac patch studies have focused on ischemic heart failure, where focal myocardial injury may be particularly amenable to localized remuscularization strategies. Published clinical studies of pluripotent stem cell-derived cardiac patches, including early human trials in Japan and Germany, are summarized in Table 2. Whether similar benefits can be achieved in non-ischemic cardiomyopathy, characterized by more diffuse myocardial dysfunction, remains less well defined and will require dedicated investigation in future trials. Table 2Published clinical studies of pluripotent stem cell-derived cardiac patchesTrial/studyDesign (patient population)Patch productOutcomes and statusMenasché et al. 2014–2018 [23]Phase I (n = 6), France. Ischemic HF patients undergoing CABG.ESC-derived cardiac progenitors in fibrin patch; immunosuppression.Feasible and safe. No graft-related arrhythmias were reported. At 1 year, trend toward improved regional wall motion.Osaka University, 2019 [24,25].Phase I (initial 3 patients), Japan. End-stage ischemic cardiomyopathy.3 allogeneic hiPSC-CM cell sheets (~ 3.3 × 10⁷ cells each); immunosuppression 3 months.Safety: No serious adverse events, teratoma, or arrhythmia. Efficacy: 2/3 patients with ↑ LVEF & perfusion; all had improved symptoms (NYHA III→II). Anti-donor antibodies detected. Primarily paracrine mechanism. Ongoing.Zimmermann/Repairon BioVAT-HF, 2020 [2,21]Phase I/II (ongoing), Germany. Advanced HF (NYHA III-IV).Allogeneic EHM patches (up to 20, ~ 800 M hiPSC-CMs + stromal cells in collagen); continuous immunosuppression.Initial result (1st patient): Feasible. Patches engrafted, vascularized, and viable at 1 year. Improved functional class. No graft-related arrhythmias or tumors. Trial recruiting (target ~ 50 patients).Heartseed LAPIS, 2022 [18]Phase I/II, Japan. Ischemic cardiomyopathy (EF 30–50%) with CABG.Allogeneic hiPSC-derived ventricular CM spheroids injected into LV wall during CABG; immunosuppression.Early 6-month data (first 2 patients): ↑ LVEF and ↓ LV volumes; improved NYHA class. No serious arrhythmias reported (high purity of ventricular cells used). Ongoing dose-escalation.HF heart failure, CABG coronary artery bypass grafting, ESC embryonic stem cell, GMP good manufacturing practice, LVEF left ventricular ejection fraction, NYHA New York Heart Association class, CM cardiomyocyte. Table 2Published clinical studies of pluripotent stem cell-derived cardiac patchesTrial/studyDesign (patient population)Patch productOutcomes and statusMenasché et al. 2014–2018 [23]Phase I (n = 6), France. Ischemic HF patients undergoing CABG.ESC-derived cardiac progenitors in fibrin patch; immunosuppression.Feasible and safe. No graft-related arrhythmias were reported. At 1 year, trend toward improved regional wall motion.Osaka University, 2019 [24,25].Phase I (initial 3 patients), Japan. End-stage ischemic cardiomyopathy.3 allogeneic hiPSC-CM cell sheets (~ 3.3 × 10⁷ cells each); immunosuppression 3 months.Safety: No serious adverse events, teratoma, or arrhythmia. Efficacy: 2/3 patients with ↑ LVEF & perfusion; all had improved symptoms (NYHA III→II). Anti-donor antibodies detected. Primarily paracrine mechanism. Ongoing.Zimmermann/Repairon BioVAT-HF, 2020 [2,21]Phase I/II (ongoing), Germany. Advanced HF (NYHA III-IV).Allogeneic EHM patches (up to 20, ~ 800 M hiPSC-CMs + stromal cells in collagen); continuous immunosuppression.Initial result (1st patient): Feasible. Patches engrafted, vascularized, and viable at 1 year. Improved functional class. No graft-related arrhythmias or tumors. Trial recruiting (target ~ 50 patients).Heartseed LAPIS, 2022 [18]Phase I/II, Japan. Ischemic cardiomyopathy (EF 30–50%) with CABG.Allogeneic hiPSC-derived ventricular CM spheroids injected into LV wall during CABG; immunosuppression.Early 6-month data (first 2 patients): ↑ LVEF and ↓ LV volumes; improved NYHA class. No serious arrhythmias reported (high purity of ventricular cells used). Ongoing dose-escalation.HF heart failure, CABG coronary artery bypass grafting, ESC embryonic stem cell, GMP good manufacturing practice, LVEF left ventricular ejection fraction, NYHA New York Heart Association class, CM cardiomyocyte. Published clinical studies of pluripotent stem cell-derived cardiac patches HF heart failure, CABG coronary artery bypass grafting, ESC embryonic stem cell, GMP good manufacturing practice, LVEF left ventricular ejection fraction, NYHA New York Heart Association class, CM cardiomyocyte. Challenges and limitations Despite promising initial results, several major challenges must be addressed for hiPSC-CM patches to become a mainstream therapy. The estimated cost per patient for current approaches is substantial, ranging from hundreds of thousands to over a million dollars, posing a major barrier to accessibility and health system reimbursement [2]. Immunogenicity and immune rejection Managing the recipient’s immune response is a central challenge for allogeneic therapies. While autologous hiPSC-CMs would be immunologically matched, their production is prohibitively expensive and time-consuming for individual patients [1]. Current trials use allogeneic lines, which necessitates managing immune rejection [21, 24, 25]. The Osaka trial’s approach of short-term immunosuppression relies on paracrine effects, while the BioVAT trial accepts lifelong immunosuppression for long-term remuscularization [21, 24]. A key goal for the field is to achieve durable graft survival without systemic immunosuppression. One promising avenue is the development of “universal” or hypoimmunogenic hiPSC lines through gene editing (e.g., CRISPR-based deletion of HLA genes) [2]. These “stealth” cells are currently in preclinical testing and could substantially reduce the immunologic burden of allogenic therapy. Cell maturation and arrhythmia risk The immature, fetal-like phenotype of hiPSC-CMs poses a considerable risk of engraftment arrhythmias due to differences in electrical properties compared to adult host cardiomyocytes [19]. The electrophysiological mismatch at the graft-host interface can create areas of slow conduction, leading to re-entrant circuits that trigger ventricular arrhythmias [4, 19]. While severe arrhythmias have not been reported in the initial patch trials, this remains a major safety concern [15, 21, 25]. Strategies to mitigate this risk include maturing the cells in vitro before implantation using a combination of electrical pacing, mechanical loading, and metabolic conditioning [6]. The use of highly purified ventricular-like cardiomyocytes, as in the Heartseed trial, can also reduce the presence of arrhythmogenic pacemaker-like cells [18]. The primary strategies employed to enhance hiPSC-CM maturation prior to implantation, along with their mechanisms and limitations, are outlined in Table 3. Structured tissue delivery in a patch format appears to lower arrhythmic risk compared to competing technologies like direct cell injections, with reported rates of sustained ventricular arrhythmias below 5% in large animal patch studies, versus over 20–30% in some injection studies [4, 19]. Table 3Strategies for maturation of hiPSC-CMsStrategyExample implementationReported outcomes and limitationsProlonged cultureExtending in vitro maintenance to > 60 daysIncreased sarcomere organization; resource-intensive, risk of senescence.Electrical stimulationChronic pacing in culture using electrode arraysEnhanced conduction velocity (e.g., + 40%), improved ion channel expression; requires specialized equipment.Mechanical loading/stretchCulturing tissues under cyclic mechanical strainPromotes sarcomere alignment, increases contractile force; may require custom bioreactors.Metabolic maturationSwitching to fatty acid-rich, glucose-poor mediaShifts toward adult-like oxidative metabolism; potential for metabolic stress.3D tissue formationCreating engineered heart muscle or spheroidsImproves cell-to-cell coupling and force generation; nutrient diffusion limits in thicker constructions.Co-culture with non-myocytesIncluding endothelial cells, fibroblasts in patchesEnhanced vascularization, structural integrity, and electrical stability. Cell ratio optimization is needed.Combined multipronged approachIntegration of multiple strategiesMost robust adult-like phenotype achieved in preclinical models; highest complexity and cost. Table 3Strategies for maturation of hiPSC-CMsStrategyExample implementationReported outcomes and limitationsProlonged cultureExtending in vitro maintenance to > 60 daysIncreased sarcomere organization; resource-intensive, risk of senescence.Electrical stimulationChronic pacing in culture using electrode arraysEnhanced conduction velocity (e.g., + 40%), improved ion channel expression; requires specialized equipment.Mechanical loading/stretchCulturing tissues under cyclic mechanical strainPromotes sarcomere alignment, increases contractile force; may require custom bioreactors.Metabolic maturationSwitching to fatty acid-rich, glucose-poor mediaShifts toward adult-like oxidative metabolism; potential for metabolic stress.3D tissue formationCreating engineered heart muscle or spheroidsImproves cell-to-cell coupling and force generation; nutrient diffusion limits in thicker constructions.Co-culture with non-myocytesIncluding endothelial cells, fibroblasts in patchesEnhanced vascularization, structural integrity, and electrical stability. Cell ratio optimization is needed.Combined multipronged approachIntegration of multiple strategiesMost robust adult-like phenotype achieved in preclinical models; highest complexity and cost. Strategies for maturation of hiPSC-CMs Vascularization, scalability, and durability For a thick patch to survive, it must rapidly establish a blood supply. Pre-seeding patches with endothelial cells or incorporating pro-angiogenic factors can promote vascularization [10]. The long-term durability of these patches is unknown. In the paracrine model, benefits may be transient, while in the remuscularization model, the graft could provide permanent new muscle, but its behavior over many years remains to be seen. Finally, manufacturing the billions of hiPSC-CMs needed per patient under GMP conditions is a major bottleneck [1]. Advances in automation and large-scale bioreactor technology are essential to reduce costs and make this therapy scalable [2, 11]. Regulatory and ethical considerations Despite encouraging advances in cardiac patch development, multiple regulatory, ethical, and patient‑level challenges must be addressed before hiPSC‑derived therapies can be broadly implemented in clinical practice. The clinical translation of hiPSC‑derived therapies faces a complex regulatory environment. Regulatory bodies like the U.S. FDA and the European Medicines Agency (EMA) have established pathways for cell and gene therapy products, but specific guidance is still evolving for pluripotent stem cell‑derived products [1, 2, 20]. Key regulatory concerns include ensuring the absence of tumorigenic cells, demonstrating product consistency, and defining appropriate potency assays. Beyond regulatory approval, ethical considerations are also equally improvement. Informed consent for these therapies must clearly articulate the uncertainties and potential long‑term risks [2]. Furthermore, the high cost raises significant issues of justice and equitable access. The decision to use allogeneic versus autologous cells also involves an ethical trade‑off between accessibility and potential immunogenicity [1]. In addition to regulatory and ethical considerations, the patient‑level burden of therapy represents a critical translational concern. From the patient’s perspective, the potential benefits must be weighed against the significant burdens of surgery, intensive long‑term monitoring, and, in some cases, the quality‑of‑life impacts of lifelong immunosuppression [21]. Future directions and conclusion The future of cardiac patch therapy will require synchronized advances on several fronts. Bioprocessing must be scaled up through automation and bioreactor‑based differentiation to dramatically lower per‑patient costs [1, 2]. Cost, scalability, and equitable access remain major barriers to the widespread clinical adoption of hiPSC-derived cardiac patches. Current manufacturing processes are resource-intensive and require stringent quality control, contributing to high per-patient costs. Ongoing efforts to address these challenges include automation of cell production, closed-system bioreactor platforms, and the development of standardized, off-the-shelf allogeneic products. In parallel, gene-edited hypoimmunogenic hiPSC lines may reduce the need for long-term immunosuppression, further improving safety and accessibility. Continued innovation in manufacturing efficiency and regulatory harmonization will be critical for translating cardiac patch therapies from highly specialized interventions into broadly available treatments. In parallel, the development of 4D biomaterials that adapt to local mechanical and biochemical cues offers new opportunities for dynamic integration and long‑term remodeling [13]. Emerging bioengineering and metabolic‑conditioning methods continue to improve cardiomyocyte maturity [7]. Future work should also leverage advances in biomaterials and scaffold design to improve long‑term integration and electrical coupling [11]. Regulatory pathways need to be clarified and harmonized internationally to streamline clinical development [2]. Long‑term follow‑up through international patient registries will be essential to monitor graft survival, function, and any late adverse events [22]. Finally, combination therapies integrating patches with gene therapy, bioelectronic interfaces, or mechanical circulatory support devices such as left ventricular assist devices (LVADs) could further optimize graft survival and function [14, 16]. Collectively, these efforts will determine whether engineered cardiac patches can transition from early clinical feasibility to durable, scalable therapies. In conclusion, engineered cardiac patches from hiPSC‑CMs represent a maturing technology at the forefront of regenerative cardiology. Early clinical trials have demonstrated feasibility, safety, and promising signals of functional benefit [17, 21]. While significant challenges related to immunogenicity, arrhythmia risk, manufacturing scale‑up, and cost remain, ongoing innovations in cell engineering, biomaterials, and clinical trial design are paving the way for this approach to potentially become a paradigm‑shifting therapy for patients with advanced heart failure [2].